Anti-tau antibodies and uses thereof

Anti-tau antibodies targeting acetylated tau protein fragment effectively inhibit aggregation and improve functions in animal models, addressing the challenge of targeting tau protein modifications for degenerative neurological diseases.

JP7595061B2Active Publication Date: 2024-12-05ADEL INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022503414
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-15
Filing Date
2020-07-13
Publication Date
2024-12-05
Estimated Expiration
2040-07-13

AI Technical Summary

Technical Problem

Developing therapeutic agents for degenerative neurological diseases such as Alzheimer's and Parkinson's is challenging due to the wide range of translational modifications in the tau protein, making it difficult to target effectively for preventing or treating these conditions.

Method used

The development of anti-tau antibodies, specifically targeting a tau protein fragment where lysine 280 is acetylated, which inhibit tau protein aggregation and improve motor and cognitive functions in animal models.

Benefits of technology

The anti-tau antibodies effectively bind to acetylated tau protein, reducing aggregation and improving motor and cognitive functions in animal models of dementia, offering potential therapeutic benefits for degenerative neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595061000004
    Figure 0007595061000004
  • Figure 0007595061000005
    Figure 0007595061000005
  • Figure 0007595061000006
    Figure 0007595061000006
Patent Text Reader

Abstract

The present invention relates to an anti-tau antibody that specifically binds to tau protein and uses thereof. The anti-tau antibody according to the present invention specifically binds to tau protein in which the lysine at position 280 is acetylated and can suppress the abnormal aggregation of tau protein. In addition, when administered to an animal model of induced dementia, the anti-tau antibody according to the present invention can improve locomotor activity and cognitive ability in the animal model. Therefore, the anti-tau antibody according to the present invention can be used in the prevention or treatment of neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to anti-tau antibodies that specifically bind to tau protein, and uses thereof. [Background technology]

[0002] Alzheimer's disease, which accounts for approximately 50% of all forms of dementia, is a degenerative neurological disorder of the head whose incidence increases in people over 65 years of age, and which is rapidly increasing worldwide due to the aging population. The cause of the onset of Alzheimer's disease is believed to be mainly due to the accumulation of β-amyloid, hyperphosphorylation of tau protein, or increased production of β-amyloid caused by presenilin 1. Among these, neuronal toxicity caused by the accumulation of β-amyloid is believed to be the major cause of the onset of Alzheimer's dementia (Hardy AJ et al., Science, 256, 184-185, 1992). However, the failure of the Phase III trial of solanezumab, a new drug candidate for Alzheimer's disease by Eli Lilly and Company, showed that the neuronal toxicity caused by the accumulation of β-amyloid was not significant. Thus, the idea that hyperphosphorylation of abnormal tau protein acts as the major cause of the onset of Alzheimer's disease has been focused on.

[0003] Tau protein is a protein that stabilizes microtubules, which are proteins that transport cellular materials. Tau protein exists in six isoforms in the human body and is abundant in neurons of the central nervous system. In addition, when a mutation occurs in tau protein, tau protein becomes hyperphosphorylated, which is known to cause abnormal accumulation of neurofibrillary tangles (NFTs) in nerve cells, thereby causing degenerative neurological diseases such as dementia and Parkinson's disease (Dong Hee Choi et al., Brain & NeuroRehabilitation, 4, 21-29, 2011).

[0004] However, human tau protein, which consists of 441 amino acids, has a wide range of sites where post-translational modifications can occur, which makes it difficult to find target parts in tau protein that exert preventive or therapeutic effects against dementia. Due to such diverse modifications, there are also difficulties in developing therapeutic agents. Summary of the Invention

[0005] Disclosure of the Invention technical challenges Therefore, the present inventors have been studying to develop an effective therapeutic agent for degenerative neurological diseases.As a result, the present inventors have found an antibody that specifically binds to the fragment of tau protein in which lysine 280 is acetylated and reduces the aggregation of tau protein.In addition, the present inventors have found that in an experiment using an animal model in which dementia is induced, the animal model administered with the antibody shows improved motor function and cognitive function.

[0006] Solutions to the issues In order to solve the above problems, in an aspect of the present invention, there is provided an anti-tau antibody or an antigen-binding fragment thereof, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1, a heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO: 2, and a heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO: 3; and (ii) a light chain variable region (VL) comprising a light chain CDR1 having the amino acid sequence represented by SEQ ID NO: 4, a light chain CDR2 having the amino acid sequence represented by SEQ ID NO: 5, and a light chain CDR3 having the amino acid sequence represented by SEQ ID NO: 6.

[0007] In another aspect of the invention, there is provided an anti-tau antibody, or an antigen-binding fragment thereof, or a polynucleotide encoding the heavy chain variable region and / or the light chain variable region of an anti-tau antibody. In another aspect of the invention, there is provided an expression vector comprising the polynucleotide. In yet another aspect of the invention, a host cell into which the expression vector is introduced is provided.

[0008] In yet another aspect of the invention, a method for producing an anti-tau antibody or antigen-binding fragment thereof is provided, the method comprising culturing a host cell. In yet another aspect of the invention, there is provided a hybridoma having the accession number KCTC 14155BP. In yet another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a degenerative neurological disease, the pharmaceutical composition comprising, as an active ingredient, an anti-tau antibody or an antigen-binding fragment thereof.

[0009] In yet another aspect of the invention, a composition for diagnosing a degenerative neurological disease is provided, the composition comprising an anti-tau antibody or an antigen-binding fragment thereof. In yet another aspect of the invention, a kit for preventing, treating or diagnosing a degenerative neurological disease is provided, the kit comprising an antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, or a host cell.

[0010] Advantageous Effects of the Invention The anti-tau antibody according to the present invention can specifically bind to tau protein in which lysine 280 is acetylated, and inhibits the aggregation of abnormal tau protein.In addition, when the anti-tau antibody according to the present invention is administered to an animal model in which dementia is induced, the anti-tau antibody can improve the motor function and cognitive function of the animal model.Therefore, the anti-tau antibody according to the present invention can be advantageously used to prevent or treat degenerative neurological diseases. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 illustrates diagrammatically the tau protein fragment K280-ac prepared in one embodiment of the present invention. [Diagram 2]FIG. 2 is a schematic diagram of the expression vector pET-21b-Tau(K18) used in one embodiment of the present invention. [Diagram 3] FIG. 3 illustrates the results of a Western blot test carried out to select monoclonal antibodies that specifically bind to the protein fragment K280-ac and to identify the binding between the antibodies and the protein fragment K280-ac. [Figure 4] FIG. 4 illustrates the results of an ELISA test carried out to identify the binding between the antibody and the protein fragment K280-ac in order to select a monoclonal antibody that specifically binds to the protein fragment K280-ac. [Diagram 5] FIG. 5 illustrates the results of a study conducted to identify whether the selected antibody ADEL-Y01 binds to acetylated wild-type tau protein (Tau) and to alanine-substituted tau protein at amino acid position 280, lysine (Tau K280A).

[0012] [Figure 6] FIG. 6 illustrates the results of studies performed to identify whether acetylated and non-acetylated wild-type tau proteins specifically bind to the ADEL-Y01h_v01 antibody. [Figure 7] FIG. 7 illustrates the dissociation constant (Kd) values ​​measured using the Octet® K2 system to identify the affinity between the ADEL-Y01m antibody and the protein fragment K280-ac. [Figure 8] FIG. 8 illustrates the results of an ELISA test carried out to identify the binding between the ADEL-Y01h antibody (v01-v12) and the protein fragment K280-ac. [Figure 9]FIG. 9 illustrates the levels and patterns of expression of tau protein (Tau5) and acetylated tau protein (Tau-acK208) in brain tissue of normal (wild type) and demented (Tau P301L) mice aged 4 or 12 months. [Figure 10] FIG. 10 illustrates the experimental schedule for identifying the behavioral improving effects achieved after intracerebroventricular administration of ADEL-Y01m antibody using a dementia-induced mouse model.

[0013] [Figure 11] FIG. 11 shows the results of a nesting building test in which ADEL-Y01m antibody was administered intracerebroventricularly to a dementia-induced mouse model (***p<0.001). [Figure 12] FIG. 12 illustrates the results of a Y-maze test in which ADEL-Y01m antibody was administered intracerebroventricularly to a dementia-induced mouse model (*p<0.05). [Figure 13] FIG. 13 illustrates the results of a water maze test in which ADEL-Y01m antibody was administered intracerebroventricularly to a dementia-induced mouse model. [Figure 14] FIG. 14 shows the time spent in each zone in a water maze test in which ADEL-Y01m antibody was intracerebroventricularly administered to a dementia-induced mouse model (**p<0.01). [Figure 15] FIG. 15 shows the results of a grip strength test in which ADEL-Y01m antibody was administered intracerebroventricularly to a dementia-induced mouse model (*p<0.05, **p<0.01).

[0014] [Figure 16] FIG. 16 illustrates the experimental schedule for identifying the behavioral improving effects achieved after intraperitoneal administration of ADEL-Y01m antibody using a dementia-induced mouse model. [Figure 17] FIG. 17 shows the results of a nest-building test in which ADEL-Y01m antibody was intraperitoneally administered to a dementia-induced mouse model (*p<0.05, **p<0.01). [Figure 18]FIG. 18 illustrates the results of a Y-maze test in which ADEL-Y01m antibody was intraperitoneally administered to a dementia-induced mouse model (*p<0.05). [Figure 19] FIG. 19 illustrates the results of a water maze test in which the ADEL-Y01m antibody was intraperitoneally administered to a dementia-induced mouse model. [Figure 20] FIG. 20 illustrates the time spent staying in each zone in the water maze test (*p<0.05), where ADEL-Y01m antibody is intraperitoneally administered to the dementia-induced mouse model before performing the water maze test.

[0015] [Figure 21] FIG. 21 illustrates the results of immunoprecipitation and Western blot studies performed to identify binding between ADEL-Y01m antibody and acetylated tau protein (Tau-acK280) expressed in cerebral cortex and hippocampus tissues of normal mice (wild type) or a dementia-induced mouse model (Tau P301L). [Figure 22] FIG. 22 illustrates photographs taken after subjecting brain tissue from normal elderly individuals and brain tissue from patients with Alzheimer's disease to immunohistochemical staining with ADEL-Y01m antibody. [Figure 23A] FIG. 23A illustrates the results of a study conducted to identify expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and amyloid-β in brain tissue of normal elderly individuals or patients with Alzheimer's disease. [Figure 23B] FIG. 23B illustrates the results of a study conducted to identify binding between the ADEL-Y01m antibody and acetylated tau protein expressed in normal aged brain tissue or brain tissue of patients with Alzheimer's disease (*p<0.05). [Figure 24]FIG. 24 illustrates the results of a study conducted to identify the expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and phosphorylated tau protein (pSer396) in brain tissue from normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody. [Diagram 25] FIG. 25 illustrates the expression levels of total tau protein (Tau5) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody (*p<0.05, ***p<0.001).

[0016] [Figure 26] FIG. 26 illustrates the expression levels of phosphorylated tau protein (pSer396) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody (**p<0.01). [Figure 27] FIG. 27 illustrates the expression levels of acetylated tau protein (Tau-acK280) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody. [Figure 28] FIG. 28 illustrates photographs showing brain tissue immunostained with ADEL-Y01m antibody, where the brain tissue was obtained from normal mice, a dementia-induced mouse model, and a dementia-induced mouse model (Tau-P301L-ADEL-Y01m) administered intracerebroventricularly with ADEL-Y01m antibody. [Figure 29] FIG. 29 illustrates the expression levels of AT8 and phosphorylated tau protein (pT231) in brain tissue from normal mice, a dementia-induced mouse model, and a dementia-induced mouse model (Tau-P301L-ADEL-Y01m) administered intracerebroventricularly with ADEL-Y01m antibody (*p<0.05). [Diagram 30]FIG. 30 illustrates the expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and phosphorylated tau protein (pT231) in brain tissue from normal mice, a dementia-induced mouse model, and a dementia-induced mouse model (Tau-P301L-ADEL-Y01m) administered intraperitoneally with ADEL-Y01m antibody.

[0017] [Diagram 31] FIG. 31 illustrates the expression levels of total tau protein (Tau5) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Diagram 32] FIG. 32 illustrates the expression levels of acetylated tau protein (Tau-acK280) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Diagram 33] FIG. 33 illustrates the expression levels of phosphorylated tau protein (pT231) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Diagram 34] FIG. 34 illustrates the expression levels of synapse-related proteins (PSD95 and synapsin-1) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody. [Diagram 35] FIG. 35 illustrates the expression levels of PSD95 in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody (*p<0.05).

[0018] [Diagram 36] FIG. 36 illustrates the expression levels of synapsin-1 in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intracerebroventricularly with ADEL-Y01m antibody (*p<0.05). [Figure 37] FIG. 37 illustrates the expression levels of synapse-related proteins (PSD95 and synapsin-1) in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody. [Figure 38] FIG. 38 illustrates the expression levels of PSD95 in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Figure 39] FIG. 39 illustrates the expression levels of synapsin-1 in brain tissues of normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Diagram 40] FIG. 40 illustrates the results of tests conducted to determine whether the ADEL-Y01m antibody penetrates brain tissue in normal mice, a dementia-induced mouse model, and a dementia-induced mouse model administered ADEL-Y01m antibody intraperitoneally, and whether the antibody binds to tau protein.

[0019] [Diagram 41] FIG. 41 illustrates the experimental schedule for identifying the behavioral improving effects achieved after intracerebroventricular administration of ADEL-Y01m antibody using an aged dementia-induced mouse model. [Diagram 42] FIG. 42 illustrates the results of the nest building test when ADEL-Y01m antibody was administered intracerebroventricularly to an aged dementia-induced mouse model (*p<0.05). [Diagram 43] FIG. 43 illustrates the results of a Y-maze test when ADEL-Y01m antibody was administered intracerebroventricularly to an aged dementia-induced mouse model (*p<0.05). [Diagram 44] FIG. 44 illustrates the time spent in each zone in a water maze test when ADEL-Y01m antibody was administered intracerebroventricularly to an aged dementia-induced mouse model (*p<0.05). [Diagram 45]FIG. 45 illustrates the expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and phosphorylated tau protein (pT231) in brain tissue from normal mice, an aged dementia-induced mouse model, and an aged dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody.

[0020] [Figure 46] FIG. 46 illustrates the expression levels of total tau protein (Tau5) in brain tissues of normal mice, aged dementia-induced mouse models, and aged dementia-induced mouse models administered intraperitoneally with ADEL-Y01m antibody (*p<0.05, **p<0.01). [Figure 47] FIG. 47 illustrates the expression levels of acetylated tau protein (Tau-acK280) in brain tissues of normal mice, aged dementia-induced mouse models, and aged dementia-induced mouse models administered intraperitoneally with ADEL-Y01m antibody (**p<0.01). [Figure 48] FIG. 48 illustrates the expression levels of phosphorylated total tau protein (pT231) in brain tissues of normal mice, aged dementia-induced mouse models, and aged dementia-induced mouse models administered intraperitoneally with ADEL-Y01m antibody (*p<0.05). [Figure 49] FIG. 49 illustrates the results of tests performed on each fraction to identify insoluble tau aggregates in the cerebral cortex of normal mice, an aged dementia-induced mouse model, and an aged dementia-induced mouse model administered intraperitoneally with ADEL-Y01m antibody. [Figure 50] FIG. 50 illustrates the expression levels of hemagglutinin (HA), total tau protein (Tau5), and acetylated tau protein (Tau-acK280) as identified by Western blot studies performed after lysis of donor cells treated with acetylated tau protein.

[0021] [Figure 51]FIG. 51 illustrates the expression levels of hemagglutinin (HA), total tau protein (Tau5), and acetylated tau protein (Tau-acK280) as identified by Western blot studies performed after obtaining media from donor cells treated with acetylated tau protein. [Figure 52] FIG. 52 illustrates intracellular tau protein aggregates identified by Western blot analysis performed after applying cultures of donor cells treated with acetylated tau protein to neurons and lysing the neurons after 1 or 20 hours. [Figure 53] FIG. 53 illustrates intracellular tau protein aggregates identified by Western blot and immunoprecipitation studies after application of cultures of donor cells treated with acetylated tau protein to neurons and lysis of the neurons 1 or 20 hours later. [Figure 54] FIG. 54 illustrates the effect of inhibiting tau protein seeding as identified by FRET following treatment of Tau-RD-P301S FRET biosensor cells with protein fragment K280-ac or its aggregates and ADEL-Y01h01_v01 antibody (**p<0.01, ***p<0.001). [Figure 55] FIG. 55 illustrates the effect of inhibiting tau protein seeding as identified by fluorescence resonance energy transfer (FRET) following treatment of Tau-RD-P301S FRET biosensor cells with a sarkosyl-insoluble fraction from a patient with Alzheimer's disease and with ADEL-Y01h01_v01 antibody (**p<0.01).

[0022] [Figure 56] FIG. 56 illustrates a photograph showing brain tissue immunostained with anti-AT8 antibody, where the brain tissue is extracted after a sarkosyl-insoluble fraction from a patient with Alzheimer's disease is administered into the CA1 layer in the left hippocampus of a Tau-P301L dementia mouse (Ipsi: ipsilateral, Contra: contralateral). [Figure 57]FIG. 57 illustrates a photograph showing brain tissue immunostained with anti-AT8 antibody, where the brain tissue is extracted after a sarkosyl-insoluble fraction from a patient with Alzheimer's disease is administered into the CA1 layer in the left hippocampus of a Tau-P301L dementia mouse (DG: dentate gyrus, EC: entorhinal cortex). [Figure 58] Figures 58 and 59 are graphs showing the extent to which brain tissue is immunostained with anti-AT8 antibody, where brain tissue is extracted after a sarkosyl-insoluble fraction from a patient with Alzheimer's disease is administered into the CA1 layer in the left hippocampus of Tau-P301L dementia mice (*p<0.05, **p<0.01). [Figure 59] Figures 58 and 59 are graphs showing the extent to which brain tissue is immunostained with anti-AT8 antibody, where brain tissue is extracted after a sarkosyl-insoluble fraction from a patient with Alzheimer's disease is administered into the CA1 layer in the left hippocampus of Tau-P301L dementia mice (*p<0.05, **p<0.01). [Figure 60] FIG. 60 illustrates the results of a Thioflavin-T assay performed to identify changes in the aggregation of acetylated tau protein after treatment of acetylated tau protein with IgG or ADEL-Y01m antibody.

[0023] [Figure 61] FIG. 61 illustrates the results of a study performed to identify changes in the amount of aggregated acetylated tau protein (Tau-acK280) after treatment of tau protein (K18), acetylated tau protein (K18+P300), and aggregated acetylated tau protein (K18+P300+heparin) with ADEL-Y01m antibody. [Figure 62] FIG. 62 is a graph showing lactate dehydrogenase (LDH) activity in supernatants obtained after treatment of neuronal cells from mice treated with IgG or ADEL-Y01m antibody with acetylated tau protein aggregates (***p<0.001). [Figure 63]FIG. 63 is a graph showing the survival rate of neurons after treatment of acetylated tau protein aggregates in neurons from mice treated with IgG or ADEL-Y01m antibody (*p<0.05, ***p<0.001). [Figure 64] FIG. 64 is a graph showing microglial HiLyte™ Fluor 488 fluorescence after treatment of microglia from mice treated with IgG or ADEL-Y01m antibody with HiLyte™ Fluor 488-labeled acetylated tau protein aggregates. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Detailed Description of the Invention Hereinafter, the present invention will be described in detail. In one aspect of the invention, an anti-tau antibody or antigen-binding fragment thereof is provided, which comprises a heavy chain variable region (VH) comprising a heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO:1, a heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO:2, and a heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO:3, and a light chain variable region (VL) comprising a light chain CDR1 having the amino acid sequence represented by SEQ ID NO:4, a light chain CDR2 having the amino acid sequence represented by SEQ ID NO:5, and a light chain CDR3 having the amino acid sequence represented by SEQ ID NO:6.

[0025] The term "antibody" as used herein means an immune protein that can bind to an antigen and thereby block the action of the antigen or remove the antigen. There are five types of antibodies: IgM, IgD, IgG, IgA and IgE, which contain heavy chains, μ, δ, γ, α and ε, respectively, generated by heavy chain constant region genes. In antibody-based technologies, IgG is mainly used. IgG has four isotypes: IgG1, IgG2, IgG3 and IgG4, whose structural and functional characteristics can differ.

[0026] IgG forms a Y-shaped stable structure (molecular weight: about 150 kDa) composed of two heavy chain (about 50 kDa) proteins and two light chain (about 25 kDa) proteins. In an antibody, the light and heavy chains consist of a variable region whose amino acid sequence differs from antibody to antibody, and a constant region whose amino acid sequence is the same between antibodies. In the heavy chain constant region, there are CH1, H (hinge), CH2 and CH3 domains. Each of the domains is composed of two β-sheets, and the domains are linked to each other via intermolecular disulfide bonds. The two variable regions of the light and light chains combine to form an antigen-binding site. The antigen-binding site is present in the two Y-shaped arms. The part that can bind to antigen is called Fab (fragment antibody binding), and the part that does not bind to antigen is called Fc (fragment crystallizable). Fab and Fc are linked to each other via a flexible hinge region.

[0027] The term "CDR" as used herein refers to a hypervariable region in the variable region of the heavy and light chains of an antibody, the amino acid sequence of which differs from antibody to antibody, where the site binds to an antigen. In the three-dimensional structure of an antibody, CDR is formed as a loop on the surface of the antibody, and under the loop, there is a framework region (FR) to structurally support CDR. There are three loop structures in the heavy chain and three loop structures in the light chain, and these six local loop structures are combined together to directly contact the antigen.

[0028] The heavy chain variable region may comprise any one amino acid sequence selected from the group consisting of SEQ ID NOs: 7 to 11, and the light chain variable region may comprise any one amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 15.

[0029] In addition, the anti-tau antibody or antigen-binding fragment thereof may be any one selected from the following group: an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:7 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:12; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 14; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 15; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14; and An anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15.

[0030] When the CDR1, CDR2 and CDR3 of the light chain variable region or the heavy chain variable region are the same, the framework region can be modified. In particular, a part of the amino acid sequence of the framework region may be modified to prepare a humanized antibody.

[0031] The amino acid sequences and SEQ ID NOs of anti-tau antibodies according to examples of the invention are summarized in Tables 1 and 2 below. [Table 1]

[0032] [Table 2]

[0033] The nucleotide sequences of anti-tau antibodies according to examples of the invention are summarized in Table 3 below. [Table 3] The term "ADEL-Y01m", as used herein, relates to a mouse antibody that specifically binds to a protein fragment in which the 280th amino acid in the amino acid sequence section of the 275th to 286th amino acids of the tau protein represented by SEQ ID NO: 25 is acetylated. In addition, the term "ADEL-Y01h", as used herein, refers to an antibody obtained by humanizing the ADEL-Y01m antibody.

[0034] The antigen-binding fragment of the antibody may be any one selected from the group consisting of Fab, scFv, F(ab')2 and Fv. The fragment refers to the antigen-binding domain excluding the crystallizable region (Fc region) having the function (effector function) of transmitting the stimulation caused by binding to the antigen to cells, complement, etc., and may include third-generation fragments such as single domain antibodies and minibodies.

[0035] Since the size of the fragment is smaller than that of the complete IgG, the fragment has the advantage of having a good penetration rate into the blood-brain barrier, and since the fragment can be produced by bacteria, the fragment has the advantage of having a low production cost. In addition, since the antibody fragment lacks Fc, the antibody fragment is used when the ability to transmit the stimulation caused by binding to the antigen to cells, complement, etc. is not desired. Due to the short half-life in the human body, the fragment is suitable for in vivo diagnosis. However, when some basic, acidic or neutral amino acids are replaced with each other among the amino acids constituting the antibody, the isoelectric point (pI) inherent to the antibody itself may change. Such a change in the isoelectric point of the antibody may result in changes such as a reduction in the toxic side effects of the antibody in vivo or an increase in water solubility. Therefore, in the case of therapeutic antibodies, the complete IgG may be used in consideration of its affinity or structural form.

[0036] The heavy chain variable region of the anti-tau antibody or an antigen-binding fragment thereof may have a heavy chain variable region sequence comprising any one of the amino acid sequences selected from SEQ ID NOs: 7 to 11, or it may have 95%, 97%, 98% or 99% homology to the heavy chain variable region sequence.

[0037] The light chain variable region of the anti-tau antibody or an antigen-binding fragment thereof may have a light chain variable region sequence comprising any one of the amino acid sequences selected from SEQ ID NOs: 12 to 15, or it may have at least 95%, 97%, 98% or 99% homology to the light chain variable region sequence.

[0038] The anti-tau antibody or antigen-binding fragment thereof may have at least 95%, 97%, 98% or 99% homology to a heavy chain variable region sequence comprising any one of the amino acid sequences selected from SEQ ID NOs: 7 to 11, and to a light chain variable region sequence comprising any one of the amino acid sequences selected from SEQ ID NOs: 12 to 15.

[0039] The anti-tau antibody can be easily prepared by known techniques for preparing monoclonal antibodies. The monoclonal antibody can be prepared by obtaining hybridomas using B lymphocytes from immunized animals, or by using phage display technology. However, the method for preparing the monoclonal antibody is not limited thereto.

[0040] In one embodiment of the present invention, a monoclonal antibody of an anti-tau antibody can be easily prepared as a hybridoma cell line by preparing B lymphocytes obtained by injecting a mouse with a protein fragment (K280-ac) having an amino acid sequence section from amino acids 275 to 286 in the amino acid sequence of wild-type tau protein of SEQ ID NO: 25, in which the 280th amino acid is acetylated.

[0041] In another aspect of the present invention, a polynucleotide is provided that encodes an anti-tau antibody or an antigen-binding fragment thereof. In yet another aspect of the present invention, a polynucleotide is provided that encodes a heavy chain or a light chain of an antibody comprising a heavy chain variable region and a light chain variable region of an anti-tau antibody or an antigen-binding fragment thereof. Specifically, the polynucleotide may comprise any one of the nucleotide sequences selected from the group consisting of SEQ ID NOs: 16 to 20, and / or any one of the nucleotide sequences selected from the group consisting of SEQ ID NOs: 21 to 24.

[0042] The polynucleotide may be any one selected from the following group: A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 16 and / or the nucleotide sequence represented by SEQ ID NO: 21; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 17 and / or the nucleotide sequence represented by SEQ ID NO: 22; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:17 and / or the nucleotide sequence represented by SEQ ID NO:23; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:17 and / or the nucleotide sequence represented by SEQ ID NO:24; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 18 and / or the nucleotide sequence represented by SEQ ID NO: 22; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 18 and / or the nucleotide sequence represented by SEQ ID NO: 23; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 18 and / or the nucleotide sequence represented by SEQ ID NO: 24; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 19 and / or the nucleotide sequence represented by SEQ ID NO: 22; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 19 and / or the nucleotide sequence represented by SEQ ID NO: 23; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:19 and / or the nucleotide sequence represented by SEQ ID NO:24; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:20 and / or the nucleotide sequence represented by SEQ ID NO:22; A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:20 and / or the nucleotide sequence represented by SEQ ID NO:23; and A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:20 and / or the nucleotide sequence represented by SEQ ID NO:24.

[0043] Polynucleotide can be modified by at least one base substitution, deletion or insertion, or combination thereof.When nucleotide sequence is prepared by chemical synthesis, it can use synthesis methods well known in the art, such as those described in Engels and Uhlmann, Angew Chem IntEd Engl., 37:73-127, 1988.Such methods can include triester method, phosphite method, phosphoramidite method and H-phosphate method, PCR and other autoprimer methods, oligonucleotide synthesis on solid phase, etc.

[0044] In yet another aspect of the present invention, an expression vector comprising a polynucleotide is provided. The expression vector may be a plasmid DNA, a phage DNA, etc., and may also include commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), E. coli-derived plasmids (pYG601BR322, pBR325, pUC118, pUC119, etc.), Bacillus subtilis-derived plasmids (pUB110, pTP5, etc.), yeast-derived plasmids (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), animal virus vectors (retrovirus, adenovirus, vaccinia virus, etc.), insect virus vectors (baculovirus), etc. In the expression vector, the expression level, modification, etc. of a protein vary depending on the host cell, and therefore it is preferable to select and use the most suitable host cell for the purpose.

[0045] In yet another aspect of the present invention, a host cell comprising expression vector is provided.Host cells for transformed cells can include, but are not limited to, cells of mammalian, plant, insect, fungal or bacterial origin.As mammalian cells, CHO cells, F2N cells, CSO cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, HEK293 cells, HEK293T cells, etc. can be used; however, mammalian cells are not limited thereto.Any cell known to those skilled in the art that can be used as mammalian host cell can be used.

[0046] In addition, when an expression vector is introduced into a host cell, the following methods may be used: CaCl2 precipitation, the Hanahan method using a reducing agent called dimethyl sulfoxide (DMSO) in combination with CaCl2 precipitation to increase efficiency, electroporation, calcium phosphate precipitation, protoplast fusion, agitation with silicon carbide fibers, Agrobacterium mediated transformation, PEG mediated transformation, dextran sulfate, lipofectamine, desiccation / inhibition mediated transformation, etc.

[0047] In yet another aspect of the present invention, a method for producing an antibody or antigen-binding fragment thereof is provided, the method comprising culturing a host cell. Specifically, the production method may comprise the steps of i) culturing the host cell to obtain a culture, and ii) recovering the antibody or antigen-binding fragment thereof from the culture.

[0048] The step of culturing the host cells may be carried out using methods known in the art. In particular, the culturing may be carried out in a batch process, a fed-batch process or a repeated fed-batch process.

[0049] The step of recovering the antibody or antigen-binding fragment thereof from the culture may be carried out using methods known in the art, including centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, resolution into fractions (e.g., ammonium sulfate precipitation), chromatography (e.g., ion exchange, affinity, hydrophobic, or molecular sieve chromatography), and the like.

[0050] In yet another aspect of the present invention, a hybridoma having accession number KCTC14155BP is provided. The hybridoma having accession number KCTC14155BP is capable of producing ADEL-Y01m. For ADEL-Y01m, reference is made to the above description of the anti-tau antibody or antigen-binding fragment thereof. In yet another aspect of the present invention, a pharmaceutical composition for preventing or treating a degenerative neurological disease is provided, the pharmaceutical composition comprising an anti-tau antibody or antigen-binding fragment thereof as an active ingredient.

[0051] The degenerative neurological disease may be a tau protein-mediated neurological disease.Specifically, the tau protein-mediated neurological disease may be tauopathy, primary age-related tauopathy, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Ritiko-Bodig disease, parkinsonism, subacute sclerosing meningitis, lead encephalopathy, tuberous sclerosis, ganglioglioma, gangliocytoma, meningioangiomatosis, subacute sclerosing panencephalitis, Hallervorden-Spatz disease, or lipofuscinosis.

[0052] In addition, the tauopathy may be Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease (PiD), a group of related disorders collectively referred to as frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), Pugilistica dementia (DP), Gerstmann-Sträussler-Scheinker disease (GSSD), Lewy body disease, chronic traumatic encephalopathy (CTE), or Huntington's disease.

[0053] The pharmaceutical composition may further comprise one or more selected from the group consisting of pharma- ceutically acceptable carriers, diluents and adjuvants. Suitable carriers for pharmaceutical compositions are known to those skilled in the art and may include, but are not limited to, proteins, sugars, and the like. The carrier may be an aqueous or non-aqueous solution, suspension, and emulsion. Examples of carriers that are non-aqueous solutions may include propylene glycol, polyethylene glycol, edible oils such as olive oil, and injectable organic esters such as ethyl oleate.

[0054] Examples of carriers for aqueous solutions may include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of carriers for parenteral administration may include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Examples of carriers for intravenous injection may include electrolyte supplements such as those based on Ringer's dextrose, fluids, and nutritional supplements. Preservatives and other additives such as antibacterial agents, antioxidants, chelating agents, and inert gases may also be present. Preferred preservatives include formalin, thimerosal, neomycin, polymyxin B, and amphotericin B.

[0055] The pharmaceutical composition may further comprise an adjuvant (immunomodulator or immunopotentiator). An adjuvant refers to a compound or mixture that enhances the immune response and / or promotes absorption after inoculation, and may include any absorption enhancer. Acceptable adjuvants include, but are not limited to, Freund's complete adjuvant, Freund's incomplete adjuvant, saponin, mineral gels such as aluminum hydroxide, surfactants such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like.

[0056] The pharmaceutical composition may be administered through any one of the routes of administration selected from the group consisting of intracerebral, intraventricular, intraperitoneal, transdermal, intramuscular, intradural, intravenous, subcutaneous, and nasal routes of administration, and is preferably administered by the intracerebral, intraventricular, intradural or intraperitoneal route.

[0057] In particular, intracerebral, intraventricular or intrathecal administration can be useful in that it does not have to consider the problem of blood-brain barrier (BBB) ​​penetration.In addition, intracerebral administration can be used when it is desired to know the effect of a drug on a specific area in the brain by directly administering a small amount of drug to that area.Intraventricular administration is a method of administering a drug to the ventricle, and can be used when it is desired to know the effect of a drug on the entire area of ​​the brain.In addition, intrathecal administration is a method of injecting a drug into the spinal canal by inserting a needle into the space around the spinal cord between two vertebrae at the bottom of the spine, and can be used when it is desired that the drug provides a rapid or local effect on the brain, spinal cord, or the tissue layer (meninges) that covers the brain or spinal cord.

[0058] According to one aspect of the present invention, the antibody of the present invention effectively improved motor and cognitive functions in an animal model with induced dementia through intraperitoneal and intracerebroventricular administration.

[0059] The pharmaceutical composition is administered in a therapeutically effective amount. The term "therapeutically effective amount" as used herein means an amount sufficient to allow the pharmaceutical composition to exert a therapeutic effect without causing side effects or severe or excessive immune response. The level of the effective amount can vary depending on a variety of factors, including the disorder to be treated, the severity of the disorder, the activity of the specific compound, the route of administration, the rate at which the protein is eliminated, the duration of treatment, the drug used in combination with or simultaneously with the protein, the age, weight, sex, dietary cycle, general health condition of the individual, and factors known in the medical field.

[0060] The dosage of the pharmaceutical composition is determined as desired, taking into consideration the age, sex, and condition of the patient, the degree of absorption of the active ingredient in the body, the rate of inactivation, and drugs used in combination. The pharmaceutical composition may be administered in an amount of 0.0001 mg / kg (body weight) to 300 mg / kg (body weight) based on the antibody or antigen-binding fragment thereof.

[0061] In yet another aspect of the invention, a method for preventing or treating a degenerative neurological disease is provided, the method comprising the step of administering an anti-tau antibody or antigen-binding fragment thereof to an individual predicted to develop or currently developing a degenerative neurological disease.

[0062] The anti-tau antibody or antigen-binding fragment thereof is as described above. The dose of the anti-tau antibody or antigen-binding fragment thereof varies depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of disease. A single dose may be administered in an amount of about 0.001 mg / kg to 300 mg / kg on a once-a-day or once-a-week basis. The effective amount can be determined at the discretion of the physician treating the patient.

[0063] The effective amount of an anti-tau antibody or antigen-binding fragment thereof may vary depending on a variety of factors, such as the patient's age, weight, characteristics and extent of symptoms, type of current treatment, number of treatments, dosage form and route of administration, and can be readily determined by a specialist in the relevant field.

[0064] The anti-tau antibody or antigen-binding fragment thereof may be administered together with or sequentially with the pharmacological or physiological components described above, and may also be administered in combination with additional conventional therapeutic agents, where the anti-tau antibody or antigen-binding fragment thereof may be administered sequentially or simultaneously with the conventional therapeutic agent. Taking into account all of the above factors, it is important to administer the minimum amount and the amount that allows maximum effect without side effects, which can be easily determined by one skilled in the art.

[0065] In yet another aspect of the invention, a composition for diagnosing a degenerative neurological disease is provided, the composition comprising an anti-tau antibody or an antigen-binding fragment thereof. The anti-tau antibody may be an antibody that binds to modified tau protein. The antibody is described above.

[0066] In particular, it has been identified that acetylation of the 280th amino acid in the amino acid sequence of tau protein causes tau aggregation and tau protein-mediated neurological diseases. An anti-tau antibody or an antigen-binding fragment thereof binds to an epitope comprising amino acids 278 to 284 in the amino acid sequence of tau protein represented by SEQ ID NO: 25, in which the 280th amino acid is acetylated, and therefore, the anti-tau antibody or antigen-binding fragment thereof may be used to more effectively diagnose tau protein-mediated neurological diseases.

[0067] When an antibody is used, assays for identifying the amount of modified tau protein that binds thereto include, but are not limited to, Western blotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemical staining, immunoprecipitation assay, complement fixation assay, fluorescence activated cell sorter (FACS), protein chips, and the like.

[0068] In yet another aspect of the invention, a kit for preventing, treating or diagnosing a degenerative neurological disease is provided, the kit comprising an anti-tau antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, or a host cell.

[0069] In yet another aspect of the invention, a diagnostic kit for a degenerative neurological disease is provided, the kit comprising an anti-tau antibody or an antigen-binding fragment thereof.

[0070] The kit can be used to measure the expression level of modified tau protein from an individual's sample to diagnose a degenerative neurological disease. In addition, a composition, solution or device that includes an antibody and one or more other components and is suitable for an assay method may be included therein to measure the expression level of modified tau protein.

[0071] A sample may be isolated from an individual by using known processes. The term "sample" as used herein includes, but is not limited to, samples such as tissue, cells, blood and plasma, each of which has different expression levels of modified tau protein, etc.

[0072] In addition, the step of measuring the protein may be performed by Western blotting, ELISA, radioimmunoassay, isotope-labeled immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemical staining, immunoprecipitation assay, complement fixation assay, FACS, or protein chip, but the present invention is not limited thereto.

[0073] Through the above assay method, it is possible to determine tau protein-mediated neurological diseases by comparing the amount of antigen-antibody complexes formed in normal controls with the amount of antigen-antibody complexes formed in individuals.

[0074] The term "antigen-antibody complex" as used herein means a conjugate between modified tau protein and an antibody specific thereto, and the amount of antigen-antibody complex formed can be quantitatively measured through the size of the signal of the detection label. Such detection label may be selected from the group consisting of enzymes, fluorescent substances, ligands, luminescent substances, microparticles, redox molecules, and radioisotopes, but is not necessarily limited thereto. When an enzyme is used as the detection label, available enzymes include β-glucuronidase, β-D-glucosidase, β-D-galactosidase, urease, peroxidase, alkaline phosphatase, etc. Ligands include, but are not limited to, biotin derivatives, etc.

[0075] In yet another aspect of the invention, there is provided a use of an anti-tau antibody, or antigen-binding fragment thereof, for preventing or treating a degenerative neurological disease. In yet another aspect of the present invention, there is provided a use of an anti-tau antibody, or an antigen-binding fragment thereof, for the preparation of a medicament for the prevention or treatment of a degenerative neurological disease.

[0076] Hereinafter, the present invention will be described in detail by means of examples. However, the following examples are only intended to illustrate the present invention, and the present invention is not limited thereto.

[0077] I. Preparation of modified tau protein fragments and antibodies thereagainst Preparation Example 1. Preparation of modified tau protein fragments To prepare the modified tau protein fragment, a tau protein fragment consisting of 441 amino acids (2N4R) was selected, which acts in the pathogenesis of Alzheimer's disease and shows cognitive function improvement effects by active immunization in a mouse model in which the tau gene is modified. As shown in Figure 1, a section consisting of 12 amino acids was designated in the amino acid sequence of the tau protein fragment located in the microtubule binding domain.

[0078] Specifically, a protein fragment having an amino acid sequence section from 275 to 286 in which the 280th amino acid is acetylated in the wild-type tau protein amino acid sequence of SEQ ID NO: 25 was designated as K280-ac. The K280-ac protein fragment was generated by requesting Peptron Inc. to generate it.

[0079] In addition, we generated a K280-ac protein fragment with keyhole limpet hemocyanin (KLH) bound to its N-terminus by requesting ANYGEN Inc. (Nam-myeon, South Korea). The K280-ac protein fragment with KLH bound to its N-terminus was purified (91.8% purity) using a Shimadzu HPLC 10AVP system under gradient conditions of 5% to 65% acetonitrile in 0.05% TFA.

[0080] Furthermore, a protein fragment of repeat domains (RD) 1, 2, 3 and 4, comprising amino acids 244 to 372 (SEQ ID NO: 26) in the wild-type tau protein amino acid sequence of SEQ ID NO: 25, was designated as K18. The vector containing the gene encoding the K18 protein fragment was transduced into E. coli cells to produce the K18 protein fragment.

[0081] Specifically, the K18 protein fragment was produced as follows: pET-21b-Tau(K18) expression vector (FIG. 2) was first transformed into E. coli BL21(DE3) and cultured in LB medium containing ampicillin at a concentration of 50 μg / ml at a temperature of 37° C. until the optical density (OD) at a wavelength of 600 nm reached 0.6-0.8. Then, treatment with IPTG at a concentration of 0.5 mM was performed, and the resultant was cultured at a temperature of 37° C. for 3 hours and at a temperature of 18° C. for 18 hours.

[0082] After 18 hours, a single colony formed was cultured with the inoculum in 5 ml of LB medium containing 50 μg / ml of ampicillin at 37° C. and 220 rpm for about 16 hours. The inoculum was inoculated at a ratio of 1:500 into an Erlenmeyer flask containing 5 L of LB medium containing 50 μg / ml of ampicillin, and then cultured at 37° C. for 4 hours. The culture was then centrifuged at 3,500 rpm for 30 minutes. The supernatant was then removed, and the remaining pellet was frozen at −20° C.

[0083] The frozen pellet was resuspended in lysis buffer (20 mM Tris-HCl, 1 mM phenylmethylsulfonyl fluoride, pH 8.0) at 25 ml / g. The cells were lysed using a JY99-IIDN ultrasonic homogenizer at 1,500 W for 30 min. The resultant was then centrifuged at 4° C. and 15,000 rpm for 20 min, and the supernatant was filtered through a 0.45 μm filter.

[0084] The filtrate was passed through a 5 mL His-Trap SP column equilibrated with buffer A (20 mM Tris-HCl, pH 8.0), washed with 5 column volumes (CV) of buffer A to remove non-specific binding, and then eluted with 10 CV of buffer B (20 mM Tris-HCl, pH 8.0, 300 mM NaCl) using a gradient of 0 to 1 M NaCl.

[0085] The fractions containing the K18 protein fragment were collected and then filtered through a 5 mL Hi-Trap SP column equilibrated with buffer C (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 50 mM imidazole). To remove non-specific binding, washing with 10 CV of buffer C was performed. Then, elution was performed with 20 CV of buffer D (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 100 mM imidazole). The eluate containing the purified K18 protein fragment was concentrated using a 10 kDa molecular weight centrifugal filter.

[0086] Acetylated K18 protein fragment (acK18) was prepared by reacting an acetylation buffer of (2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mM, pH 7.4), 50 mM NaCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 2.5 mM EGTA, 0.1 mM EDTA with 8 μM K18 protein fragment, 125 μM acetyl-CoA, and 0.5 μg P300 enzyme (which is an acetyltransferase) at 30° C. for 3 h.

[0087] The K18 protein fragment aggregates were prepared by dissolving 25 μM of K18 protein fragment in 25 mM DTT solution for 1 h at 24° C., and stirring in a solution of (2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mM, pH 7.4), NaCl (100 mM), and heparin (25 mM) at 37° C. and 700 rpm using an Eppendorf Thermomixer C.

[0088] Preparation Example 2. Preparation of an antibody that binds to a modified tau protein fragment The antibody that specifically binds to the K280-ac protein fragment prepared in Preparation Example 1 was produced by requesting AbFrontier, a Korean mouse monoclonal antibody development company, to produce it. The B lymphocytes obtained by injecting the K280-ac protein fragment as an antigen into mice were produced as hybridoma cells. Then, cell lines that produce antibodies that specifically bind to the K280-ac protein fragment were screened through ELISA. In addition, phage display library screening was performed by antibody development researchers at a university in Korea to develop antibodies that specifically bind to the K280-ac protein fragment.

[0089] As a result, one mouse hybridoma cell line (mouse hybridoma cell line) was finally selected, and the candidates selected through phage display library screening were eliminated because they produced antibodies with lower affinity than the mouse hybridoma cell line. The antibodies produced from the mouse hybridoma cell line were checked in vitro through Western blotting and ELISA for binding to the K280-ac protein fragment.

[0090] As a result, the antibody produced by the #15E5 hybridoma cell line (clone #1) was identified as an antibody that specifically binds to the K280-ac protein fragment (Figures 3 and 4). The antibody produced by the #15E5 hybridoma cell line was finally designated as ADEL-Y01m.

[0091] Starting from this murine antibody, humanized antibodies were generated using conventional techniques including antibody variable region analysis, CDR searching, molecular modeling, human germline antibody analysis, CDR grafting and gene sequencing, and these humanized antibodies were designated ADEL-Y01h (v01-v10).

[0092] Meanwhile, the #15E5 hybridoma cell line was deposited at the Korean Collection for Type Cultures (KCTC) on March 18, 2020, and was assigned the microbial accession number KCTC14155BP.

[0093] Experimental Example 1. Identification of antigen-specific binding In order to identify the specific binding of the ADEL-Y01m antibody prepared in Preparation Example 2 to acetylated tau protein, wild-type tau protein and tau protein in which the 280th amino acid lysine was replaced with alanine (tau K280A) were acetylated in vitro. Here, the acetylation of wild-type tau protein and tau K280A protein was carried out in the same manner as in the preparation method of the acetylated K18 protein fragment in Preparation Example 1. Then, the antigen-antibody specific binding reaction of the ADEL-Y01m antibody was checked through Western blotting.

[0094] First, the concentrations of wild-type tau protein and tau K280A protein were measured through Bradford assay. Each of the proteins was mixed with 4× sample buffer (60 mM Tris-HCl [pH 6.8], 2% w / v SDS, 25% v / v glycerol, 14.4 mM v / v β-mercaptoethanol, and bromophenol blue). Then, each protein was electrophoresed on SDS-PAGE gel. The electrophoresed gel was then separated and transferred onto a PVDF membrane (BioRad, California, USA). Treatment with blocking buffer (0.1% v / v Tween-20 [PBST], 3% w / v BSA, or 5% v / v skim milk in PBS buffer) was performed, and the reaction was allowed to proceed for 1 h. Then, treatment with anti-acetyl-lysine antibody (anti-acetyl-lysine, Cell Signaling, 9441) or ADEL-Y01m antibody was performed as the primary antibody, and the reaction was allowed to proceed overnight at 4°C. The next day, the PVDF membrane was washed three times with washing buffer (0.1% v / v Tween-20 in PBS buffer [PBST]) and then treated with HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083). The PVDF membrane was treated with chemiluminescence reagent (Thermo Fisher Scientific). Then, measurement and analysis were performed using X-ray film and ImageJ software (NIH, Bethesda, MD).

[0095] As a result, it was identified that the ADEL-Y01m antibody does not bind to tau K280A protein or to acetylated tau K280A protein (FIG. 5). These results identified the ADEL-Y01m antibody as an antibody that specifically binds only to tau protein with acetylated lysine at the 280th amino acid.

[0096] In addition, to identify specific binding with the ADEL-Y01h01_v01 antibody prepared in Preparation Example 2, Western blotting was performed using the K280-ac protein fragment and the K18 protein fragment in the same manner as above, in which the ADEL-Y01h01_v01 antibody and the HRP-labeled anti-human IgG antibody (Bioxcell, BE0297) were used. As a result, it was identified that the ADEL-Y01h01_v01 antibody exhibited high antibody affinity for the K280-ac protein fragment (FIG. 6).

[0097] Experimental Example 2. Identification of antigen-antibody affinity The affinity between the K280-ac protein fragment prepared in Preparation Example 1 and the ADEL-Y01m antibody prepared in Preparation Example 2 was measured through an Octet® K2 system (Fortebio).

[0098] ADEL-Y01m antibody was immobilized on AR2G biosensor according to the manufacturer's manual. The surface of the biosensor was hydrated with water for 10 minutes and activated with a mixture of 20 mM 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 10 mM N-hydroxysulfosuccinimide (s-NHS). ADEL-Y01m antibody was immobilized on the activated biosensor with 10 mM sodium acetate buffer (pH 5.0) and quenched with 1 M ethanolamine (pH 8.0) for 5 minutes. The biosensor with immobilized ADEL-Y01m antibody was immersed in 1×PBS buffer (pH 7.4) for 60 seconds to establish a baseline. The biosensor was then immersed in wells containing various concentrations of K280-ac protein fragments (antigens) or BSA-bound peptides for 60 seconds. The biosensor was then immersed again in 1×PBS buffer (pH 7.4) for 10 min to allow dissociation to occur. Experimental data were evaluated by Octet Data Analysis (SW version: 9.0.0.10). As a result, the antigen dissociation constant (Kd) value for the affinity between the ADEL-Y01m antibody and the K280-ac protein fragment was 2.57 × 10 -10 M was measured (Figure 7). In addition, the binding of the K280-ac protein fragment prepared in Preparation Example 1 to the ADEL-Y01h (v01 to v12) antibody prepared in Preparation Example 2 was measured by ELISA.

[0099] First, the plate was treated with 250ng / well of K280-ac protein fragment, and the reaction was allowed to proceed overnight at 4°C. The next day, the plate was washed three times with washing buffer, and then treated with primary antibody at eight concentrations (2μg, 1μg, 0.5μg, 0.25μg, 0.12μg, 0.06μg, 0.03μg, 0.01μg). HRP-labeled anti-human IgG antibody was used as the secondary antibody. As a result, it was identified that the ADEL-Y01h (v01 to v10) antibody exhibited high antibody affinity for the K280-ac protein fragment (FIG. 8).

[0100] II. Identification of therapeutic effects caused by ADEL-Y01m antibody using animal models Preparation example 3. Preparation of a dementia mouse model JNPL3 mice expressing the Tau-P301L mutant gene were purchased from Taconic and backcrossed with C57bl / 6 mice for five generations in the laboratory animal room of the Asan Institute for Life Sciences (Korea). The mice were then raised under specific pathogen-free (SPE) conditions.

[0101] Experimental example 3. Identification of characteristics of a mouse model of dementia The Tau-P301L dementia mouse model used in the experiment showed differences in age-related accumulation of tau protein in brain tissue compared with normal mice. Immunoblotting was performed using the ADEL-Y01m antibody prepared in Preparation Example 2.

[0102] Brains were extracted from normal mice and Tau-P301L dementia mice, and then soluble and insoluble proteins were separated from brain tissue through Sarkosyl fractionation. Brain samples were homogenized with RA buffer B (100mM MES, 0.75M NaCl, 1mM EGTA, 0.5mM MgSO4, 2mM DTT, pH6.8+protease / phosphatase inhibitors). Samples were incubated on ice for 20 minutes and centrifuged at 9,000rpm for 20 minutes at 4°C. After centrifugation, the supernatant was collected (soluble proteins). Pellets were homogenized with extraction buffer (1% Sarkosyl, 10mM Tris, 10% sucrose, 0.85M NaCl, 1mM EGTA, pH7.4). The samples were incubated at room temperature for 1 hour and centrifuged at 13,000 rpm for 20 minutes at 4° C. After centrifugation, the supernatant was collected (tau aggregates). The separated proteins were subjected to Western blotting in the same manner as in Example 1.

[0103] As a result, it was identified that the 12-month-old dementia mouse model showed an increase in the number of acetylated tau proteins in the brain tissue. In particular, it was identified that the 4-month-old dementia mouse model showed a similar expression level of tau protein to that in normal mice, while the 12-month-old dementia mouse model showing severe dementia symptoms showed about twice the expression level of tau protein compared to normal mice (Figure 9).

[0104] Experimental Example 4. Identification of behavioral improvement effect caused by ADEL-Y01m antibody: intracerebroventricular administration To identify the therapeutic effect caused by the ADEL-Y01m antibody, the ADEL-Y01m antibody was administered to the lateral ventricle of Tau-P301L dementia mice prepared in Preparation Example 3 using an osmotic pump, according to the experimental schedule illustrated in FIG. 10.

[0105] Experimental Example 4.1. Identification of behavioral improvement effects through nest-building tests We performed a nest-building test, which can identify multimodal brain functions in mice. Specifically, two-thirds of the litter in one cage in which mice were raised were removed, and four layers of sterile cotton (5 cm x 5 cm) were placed in the cage. One mouse was allowed to enter one cage. The next morning, the degree of completion of the nest was analyzed.

[0106] Scores according to the completion of the nest were calculated by dividing the scores into 1 to 5 points. If the provided sterile cotton was maintained at 90% or more or was barely touched, the cage was calculated as 1 point; if the sterile cotton was maintained at about 50% to 90% and partially torn, the cage was calculated as 2 points; if the sterile cotton was torn at 50% or more and spread around the cage, the cage was calculated as 3 points; if the sterile cotton was torn at 90% or more and gathered at the edge of the cage, the cage was calculated as 4 points. If the sterile cotton was completely torn and a complete nest shape was formed at the edge of the cage, the cage was calculated as 5 points.

[0107] As a result, it was identified that Tau-P301L dementia mice showed a nest-building score reduction of approximately 60% compared to normal mice, and that dementia mice administered ADEL-Y01m antibody (Tau-P301L-ADEL-Y01m) showed a nest-building score similar to that of normal mice (Figure 11).

[0108] Experimental Example 4.2. Identification of behavioral improvement effects through the Y-maze test To identify the recovery of cognitive function, a Y-maze test was performed. The Y-maze test is an experiment to identify short-term memory ability. Specifically, zones A, B, and C were set in a Y-shaped box, and the mouse was allowed to move freely for 5 minutes with zone B blocked. After 1 hour, the blockage of zone B was removed, and the mouse's movement was observed for 5 minutes with all zones open.

[0109] As a result, in the case of Tau-P301L mice, the time spent in the A or C zone was less than 100 seconds, which was about 50% lower than that of normal mice. On the other hand, in the case of Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the time spent in the A or C zone was about 150 seconds, which was similar to that of normal mice. From these results, it was identified that the short-term memory ability of Tau-P301L-ADEL-Y01m dementia mice was restored (Figure 12).

[0110] Experimental Example 4.3. Identification of behavioral improvement effects through water maze testing To evaluate the learning and memory ability of mice, water maze test was performed.The equipment and program used for water maze test are the behavioral equipment owned by the experimental animal room of Asan Institute for Life Sciences.Specifically, water maze test takes a total of 5 days.Mice are trained for 4 days in the presence of platform and visual cue of platform position.

[0111] Learning was performed by filling a swimming pool (1.4 m diameter, 45 cm deep) with water (29 ± 0.5 °C) to a depth of about 26.5 cm with platform, and then adding 1.5 L of whole milk powder to make the water cloudy so that the mouse could memorize the platform by cue alone. The mouse was then accustomed to swimming freely for 60 s and rested on the platform for 1 min. The experiment was performed a total of 12 times with 4 sets at 3 different starting positions. At the end of each trial, a rest period of 30 s was given. At the end of one set, a rest period of 30 to 45 min was given.

[0112] After learning for 4 days, test is carried out on the 5th day.In the experiment for evaluation, in order to identify whether mouse often visits the platform position using only cue, the platform is not placed, and the number of stays in the area where the platform is placed is measured.In addition, mouse is made to reach the platform position within 1 minute.If mouse cannot reach the platform position within 1 minute, mouse is removed from swimming pool.

[0113] First, the time required for the mice to find the platform during the 4-day learning period was measured. As a result, in the case of Tau-P301L mice, the time required for the mice to find the platform was more than 20 seconds during the 4-day period. On the other hand, in the case of normal mice and Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the time required for the mice to find the platform was reduced to less than 20 seconds from the second day (FIG. 13).

[0114] In addition, the time spent in the NW zone where the platform was placed was evaluated on day 5. As a result, it was identified that Tau-P301L mice stayed in the NW zone for 10 seconds or less, whereas normal mice and Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody stayed in the NW zone for 20 seconds or less ( FIG. 14 ).

[0115] Experimental Example 4.4. Identification of behavioral improvement effects through grip strength testing To identify the muscle strength of mice, grip strength test was carried out. For the iron bundle used in the experiment, the behavioral equipment owned by Asan Institute for Life Sciences was used. Here, the iron bundle with a weight of 40g was used for the iron bundle. The mouse prepared in Preparation Example 3 was held by the end of the tail, and the front paws of the mouse were placed on the 40g iron bundle so that the mouse could hold the iron bundle. Then, the mouse was held by the tail and lifted to a height of about 30cm. The time that the mouse took to release the iron bundle was measured, and comparison was made for each mouse.

[0116] As a result, normal mice showed a measurement time of 20 seconds or less for grip strength, and Tau-P301L dementia mice showed a measurement time of 5 seconds or less for grip strength. In contrast, in the case of Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the measurement time for grip strength was more than 20 seconds, which was longer than that of normal mice (Figure 15). From these results, it was identified that the motor ability of Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody was restored.

[0117] Experimental Example 5. Identification of the behavioral improvement effect of ADEL-Y01m antibody: intraperitoneal administration To identify the therapeutic efficacy of ADEL-Y01m antibody, the antibody was intraperitoneally administered to Tau-P301L dementia mice prepared in Preparation Example 3 for three months according to the experimental schedule illustrated in FIG.

[0118] Experimental Example 5.1. Identification of behavioral improvement effects through nest-building tests The nest-building test, which can identify multimodal brain functions in mice, was performed in the same manner as in Experimental Example 4.1. As a result, it was identified that Tau-P301L dementia mice showed a nest-building score reduction of approximately 60% compared to normal mice, and that Tau-P301L-ADEL-Y01m dementia mice administered ADEL-Y01m antibody showed a nest-building score similar to that of normal mice (Figure 17).

[0119] Experimental Example 5.2. Identification of behavioral improvement effects through the Y-maze test To identify the recovery of cognitive function, Y-maze test was performed in the same manner as in Experimental Example 4.2. As a result, in the case of Tau-P301L mice, the time spent in A or C zone was about 80 seconds, which was about 50% lower than that of normal mice. Meanwhile, in the case of Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the time spent in A or C zone was about 110 seconds, which was similar to that of normal mice. From these results, it was identified that the short-term memory ability of Tau-P301L-ADEL-Y01m dementia mice was restored (Figure 18).

[0120] Experimental Example 5.3. Identification of behavioral improvement effects through water maze testing Water maze test was performed in the same manner as in experiment 4.3. The time required for mice to find the platform during 4 days of learning was measured. As a result, in the case of Tau-P301L mice, the time required for mice to find the platform was 20 seconds or less during 4 days. On the other hand, in the case of normal mice and Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the time required for mice to find the platform was reduced to 15 seconds or less from the third day (Figure 19).

[0121] In addition, on the fifth day, the time spent in the NW zone where the platform was placed was evaluated. As a result, it was identified that Tau-P301L mice stayed in the NW zone for 20 seconds or less, whereas normal mice and Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody stayed in the NW zone for about 25 seconds ( FIG. 20 ).

[0122] Experimental Example 6. Identification of specific binding between ADEL-Y01m antibody and modified tau protein expressed in mouse tissues I The cerebral cortex and hippocampus tissues of normal mice and Tau-P301L dementia mice prepared in Preparation Example 3 were subjected to immunoprecipitation (IP) and Western blotting using IgG and ADEL-Y01m antibodies.

[0123] First, a sample buffer was prepared by adding 1% Tx-100, 100 mM NaCl, and 50 mM HEPES to distilled water and adjusting the pH to pH 7.4. Then, the sample buffer was used to resuspend the cerebral cortex and hippocampus tissues of normal mice and Tau-P301L dementia mice, thereby obtaining resuspended samples. Each of the obtained samples was treated with IgG or ADEL-Y01m antibody, and the reaction was allowed to proceed for 24 hours. Then, the sample was treated with 100 μl of protein G-agarose beads (GE Healthcare Life Sciences), and the reaction was allowed to proceed overnight at 4°C. The next day, the sample was collected by centrifugation at 6,000 rpm for 1 minute at 4°C, and washed three times with PBS containing 0.1% Triton X-100. The sample was treated with 1× sample buffer and subjected to Western blotting. Here, Western blotting was performed in the same manner as in Experimental Example 1, using IgG, ADEL-Y01m antibody, and HRP-labeled anti-mouse IgG antibody.

[0124] As a result, it was identified that there was a specific binding reaction between the ADEL-Y01m antibody and the tau protein (Tau-acK280) in which the 280th amino acid lysine was acetylated in the cerebral cortex and hippocampus tissues of Tau-P301L dementia mice. In addition, these results confirmed that the ADEL-Y01m antibody binds well to the modified tau protein expressed in brain tissue in vivo (Figure 21).

[0125] Experimental Example 7. Identification of binding between ADEL-Y01m antibody and modified tau protein expressed in human tissues II To identify specific binding between the ADEL-Y01m antibody and modified tau protein expressed in human brain tissue, temporal cortex in brain tissues of normal elderly people and patients with Alzheimer's disease were subjected to immunohistochemical staining with the ADEL-Y01m antibody.

[0126] First, the temporal cortex of brain tissue from normal elderly subjects and patients with Alzheimer's disease was sliced ​​and attached to a slide glass. Brain tissue was provided by the Netherlands Brain Bank. The sections were washed with 1x PBS and permeabilized with 1x PBS containing 0.1% Triton X-100 for 10 minutes at room temperature. The sections were then washed and blotted with PBS containing 3% BSA for 1 hour at room temperature. The sections were washed with 1x PBS and reacted with ADEL-Y01m antibody at 4°C overnight.

[0127] The next day, sections obtained by reacting with primary antibodies overnight for diaminobenzidine (DAB) staining were washed with 1×PBS. Sections were reacted with biotinylated anti-mouse IgG antibody (Vector Laboratories, California, USA) as secondary antibody at room temperature for 1 hour. Sections were washed with 1×PBS, treated with avidin-biotin-peroxidase complex (Vector Laboratories, California, USA), and reacted. Brain tissue sections were reacted in DAB solution for 10 minutes, then washed with 1×PBS. Sections were mounted on Canada balsam (Sigma-Aldrich). Sections were imaged using a Zeiss microscope (Carl Zeiss, Oberkochen, Germany), and images were processed using an AxioVision Imaging System.

[0128] As a result, no staining with ADEL-Y01m antibody was observed in the temporal cortex of normal elderly subjects, whereas staining with ADEL-Y01m antibody was observed in the temporal cortex of patients with Alzheimer's disease. In addition, these results identified that ADEL-Y01m antibody binds well to modified tau protein expressed in brain tissue in vivo (Figure 22).

[0129] In addition, brain tissues of normal elderly people and patients with Alzheimer's disease were analyzed through Western blotting, where Western blotting was performed in the same manner as in Experimental Example 1, using anti-Tau5 antibody (Invitrogen, AHB0042), anti-acetyl-K280 antibody (Anaspec, AS-56077), anti-amyloid-β antibody (Covance, SIG-39300), anti-GAPDH antibody (Millipore, MAB374), and HRP-labeled anti-human IgG antibody.

[0130] As a result, higher expression levels of total tau protein, acetylated tau protein, and amyloid-β were observed in the brain tissue of patients with Alzheimer's disease compared to the brain tissue of normal elderly people (Figure 23A). In particular, about three times more acetylated tau protein (Tau-acK280) was observed in the brain tissue of patients with Alzheimer's disease (Figure 23B).

[0131] Experimental Example 8. Identification of the tauopathy-alleviating effect after intracerebroventricular administration of ADEL-Y01m antibody In order to identify the tauopathy alleviating effect after administration of ADEL-Y01m antibody, brain tissues of Tau-P301L dementia mice and normal mice intracerebroventricularly administered with IgG or ADEL-Y01m antibody were extracted, and the expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and tau (Ser396) obtained by phosphorylating the 396th amino acid, serine, in the amino acid sequence of tau protein were checked through Western blotting. Here, Western blotting was performed in the same manner as in Experimental Example 1, and anti-Tau5 antibody (Invitrogen, AHB0042), anti-pSer396 antibody (Thermo, 44-752G), anti-acetyl-K280 antibody (Anaspec, AS-56077), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083) were used.

[0132] As a result, it was identified that total tau protein, acetylated tau protein, and phosphorylated tau protein were present in higher amounts in the brain tissue of Tau-P301L dementia mice administered IgG intracerebroventricularly than in the brain tissue of normal mice. On the other hand, total tau protein, acetylated tau protein, and phosphorylated tau protein were present in lower amounts in the brain tissue of Tau-P301L dementia mice administered IgG intracerebroventricularly than in the brain tissue of Tau-P301L dementia mice administered IgG intracerebroventricularly (Figures 24 to 27).

[0133] In addition, immunohistochemical staining was performed to identify the expression levels of tau protein (pSer202 / pThr205) obtained by phosphorylating the 202nd amino acid serine and the 205th amino acid threonine in the amino acid sequence of tau protein, and phosphorylated tau (pT231) in mouse brain tissue. Here, immunohistochemical staining was performed in the same manner as in Experimental Example 7, and anti-AT8 antibody (Thermo, MN1020) and anti-pT231 antibody (Thermo, MN1040) were used as primary antibodies.

[0134] As a result, a higher expression level of phosphorylated tau protein was observed in the brain tissue of Tau-P301L dementia mice administered intracerebroventricularly with IgG compared to that of normal mice. Meanwhile, a lower expression level of phosphorylated tau protein was observed in the brain tissue of Tau-P301L dementia mice administered intracerebroventricularly with ADEL-Y01m antibody compared to that of Tau-P301L dementia mice administered intracerebroventricularly with IgG (Figures 28 and 29).

[0135] Experimental Example 9. Identification of the tauopathy-reducing effect after intraperitoneal administration of ADEL-Y01m antibody In order to identify the tauopathy alleviating effect after administration of ADEL-Y01m antibody, brain tissues of Tau-P301L-ADEL-Y01m dementia mice and normal mice intraperitoneally administered with IgG or ADEL-Y01m antibody at a dose of 50 mg / kg were extracted, and the expression levels of total tau protein (Tau5), acetylated tau, and phosphorylated tau (pT231) were checked through semi-denaturing Western blotting. Here, semi-denaturing Western blotting was performed in the same manner as Western blotting in Experimental Example 1, except that mouse brain tissue was mixed with 2x Laemmli sample buffer without β-mercaptoethanol. In addition, anti-Tau5 antibody (Invitrogen, AHB0042), anti-pT231 antibody (Thermo, MN1040), anti-acetyl-K280 antibody (Anaspec, AS-56077), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083) were used.

[0136] As a result, it was identified that total tau protein, phosphorylated tau protein, and oligomeric forms of acetylated tau protein were present in higher amounts in the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally than in the brain tissue of normal mice. On the other hand, total tau protein, phosphorylated tau protein, and acetylated tau protein were present in significantly lower amounts in the brain tissue of Tau-P301L-ADEL-Y01m dementia mice administered ADEL-Y01m antibody intraperitoneally than in the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally (Figures 30-33).

[0137] Experimental Example 10. Identification of synapse-improving effects caused by ADEL-Y01m antibody: intracerebroventricular administration To identify the synapse-improving effect after administration of ADEL-Y01m antibody, brain tissues of Tau-P301L dementia mice intracerebroventricularly administered with IgG or ADEL-Y01m antibody at a dose of 50 mg / kg and normal mice were extracted and Western blotting was performed for synapse-related proteins. Here, Western blotting was performed in the same manner as in Experimental Example 1, using anti-PSD95 antibody (Abcam, ab2723), anti-synapsin-1 antibody (Chemicon, MAB355), anti-β-actin antibody (Sigma, A5441), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083).

[0138] As a result, higher expression levels of PSD59 and synapsin-1 were observed in the brain tissue of Tau-P301L dementia mice administered IgG intracerebroventricularly compared to the brain tissue of normal mice. On the other hand, lower expression levels of PSD59 and synapsin-1 were observed in the brain tissue of Tau-P301L dementia mice administered ADEL-Y01m antibody intracerebroventricularly compared to the brain tissue of Tau-P301L dementia mice administered IgG intracerebroventricularly (Figures 34-36).

[0139] Experimental Example 11. Identification of synapse-improving effect caused by ADEL-Y01m antibody: intraperitoneal administration In order to identify the synapse improving effect after administration of ADEL-Y01m antibody, brain tissues of Tau-P301L dementia mice and normal mice intraperitoneally administered with IgG or ADEL-Y01m antibody at a dose of 50 mg / kg were extracted and subjected to Western blotting for synapse-related proteins. Here, Western blotting was performed in the same manner as in Experimental Example 10.

[0140] As a result, higher expression levels of PSD59 and synapsin-1 were observed in the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally compared to the brain tissue of normal mice. On the other hand, lower expression levels of PSD59 and synapsin-1 were observed in the brain tissue of Tau-P301L dementia mice administered ADEL-Y01m antibody intraperitoneally compared to the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally (Figures 37-39).

[0141] Experimental Example 12. Identification of the penetration of ADEL-Y01m antibody into brain tissue and its binding to antigens after intraperitoneal administration of ADEL-Y01m antibody In order to identify the distribution of the antibody in brain tissue after intraperitoneal administration of ADEL-Y01m antibody, Tau-P301L dementia mice, which were intraperitoneally administered with ADEL-Y01m antibody at an amount of 50 mg / kg, and normal mice were subjected to cardiac perfusion with physiological saline. Then, brain tissues were extracted from them and subjected to immunoprecipitation with protein-G Sepharose (PGS). Then, Western blotting was performed using anti-mouse IgG antibody. Here, Western blotting was performed in the same manner as in Experimental Example 1, and anti-Tau5 antibody (Invitrogen, AHB0042), anti-acetyl-K280 antibody (Anaspec, AS-56077), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083) were used.

[0142] As a result, no antibodies were detected in the brain tissue of Tau-P301L dementia mice that had been intraperitoneally administered IgG. On the other hand, the presence of antibodies was identified in the brain tissue of Tau-P301L dementia mice that had been intraperitoneally administered ADEL-Y01m antibody (Figure 40).

[0143] Experimental Example 13. Identification of behavioral improvement effects caused by ADEL-Y01m antibody in an aged dementia mouse model: intraperitoneal administration To identify the therapeutic efficacy of ADEL-Y01m antibody, aged 14-month-old mice were used in the same manner as in Preparation Example 3 to generate an aged dementia mouse model. The aged dementia mouse model was administered with the ADEL-Y01m antibody prepared in Preparation Example 2 according to the experimental schedule illustrated in FIG.

[0144] Experimental Example 13.1. Identification of behavioral improvement effects through nest-building tests The nest-building test, which can identify multimodal brain functions in mice, was performed in the same manner as in Experimental Example 4.1. As a result, it was identified that Tau-P301L dementia mice showed a nest-building score reduction of about 60% compared to normal mice, and that Tau-P301L-ADEL-Y01m dementia mice administered ADEL-Y01m antibody showed a nest-building score similar to that of normal mice (Figure 42).

[0145] Experimental Example 13.2. Identification of behavioral improvement effects through the Y-maze test To identify the recovery of cognitive function, the Y-maze test was performed in the same manner as in Experimental Example 4.2. As a result, in the case of Tau-P301L mice, the time spent in A or C zone was about 80 seconds, which was about 25% lower than that of normal mice. On the other hand, in the case of Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody, the time spent in A or C zone was about 120 seconds, which was similar to that of normal mice. From these results, it was identified that the short-term memory ability of Tau-P301L-ADEL-Y01m dementia mice was restored (Figure 43).

[0146] Experimental Example 13.3. Identification of behavioral improvement effects through water maze testing The water maze test was conducted in the same manner as in experiment 4.3. As a result, the time spent in the NW zone where the platform was placed was evaluated on the fifth day. As a result, it was identified that Tau-P301L mice stayed in the NW zone for 10 seconds or less, whereas normal mice and Tau-P301L-ADEL-Y01m dementia mice administered with ADEL-Y01m antibody stayed in the NW zone for 25 seconds or more ( FIG. 44 ).

[0147] Experimental Example 14. Identification of the tauopathy-alleviating effect caused by ADEL-Y01m antibody in an aged dementia mouse model: intraperitoneal administration In order to identify the tauopathy alleviating effect after administration of ADEL-Y01m antibody, brain tissues of aged Tau-P301L dementia mice and normal mice intraperitoneally administered with IgG or ADEL-Y01m antibody at a dose of 50mg / kg were extracted, and the expression levels of total tau protein (Tau5), acetylated tau protein (Tau-acK280), and phosphorylated tau (pT231) were checked through Western blotting. Here, Western blotting was performed in the same manner as in Experimental Example 1, using anti-Tau5 antibody (Invitrogen, AHB0042), anti-pT231 antibody (Thermo, MN1040), anti-acetyl-K280 antibody (Anaspec, AS-56077), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083).

[0148] As a result, higher expression levels of oligomeric forms of total tau protein, phosphorylated tau protein, and acetylated tau protein were observed in the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally. On the other hand, significantly lower expression levels of total tau protein, phosphorylated tau protein, and acetylated tau protein were observed in the brain tissue of Tau-P301L dementia mice administered ADEL-Y01m antibody intraperitoneally compared to the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally (Figures 45-48).

[0149] In addition, the brain tissues of aged Tau-P301L dementia mice and normal mice intraperitoneally administered with IgG or ADEL-Y01m antibody at 50 mg / kg were extracted, and cerebral cortex tissues were partially isolated from them using formic acid. In the cerebral cortex tissues, insoluble tau aggregates were checked through semi-denaturing Western blotting. Here, semi-denaturing Western blotting was performed in the same manner as in Experimental Example 9.

[0150] As a result, an increase in insoluble tau aggregates was observed in the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally.On the other hand, a significant decrease in insoluble tau aggregates was observed in the brain tissue of Tau-P301L dementia mice administered ADEL-Y01m antibody intraperitoneally, compared with the brain tissue of Tau-P301L dementia mice administered IgG intraperitoneally (Figure 49).

[0151] III. Identification of the inhibitory effect of anti-tau antibodies on tau seeding Experimental Example 15. Identification of tau aggregation and seeding of acetylated tau protein First, wild-type tau protein (Tau) was reacted with the acetyltransferase P300 enzyme in vitro. Cultured neurons were treated with acetylated tau protein (Tau-K280-ac) reacted with P300. To identify whether acetylated tau protein induces intracellular aggregation, Western blotting was performed on donor cell lysates using anti-HA antibody (Sigma-Aldrich, #11867423001) after 1 or 20 hours of treatment with acetylated or wild-type tau protein.

[0152] Here, Western blotting was performed in the same manner as in Experimental Example 1, using anti-Tau5 antibody (Invitrogen, AHB0042), anti-acetyl-K280 antibody (Anaspec, AS-56077), anti-β-actin antibody (Sigma, A5441), anti-HA antibody (Sigma, #11867423001), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083). As a result, an increase in the aggregation of total tau protein (Tau5) and acetylated tau protein (Tau-acK280) was observed in the lysate of donor cells treated with acetylated tau protein (Figure 50).

[0153] In addition, to identify whether the amount of tau protein secreted outside the cells was altered, the medium of donor cells was subjected to immunoprecipitation with anti-HA antibody (Sigma-Aldrich, #11867423001) followed by Western blotting.

[0154] Specifically, the donor cell medium was centrifuged at 13,000 rpm for 1 minute to remove cell debris. The donor cell medium was then treated with protein G-agarose beads (GE Healthcare Life Sciences, Piscataway, NJ, USA) and reacted at 4°C for 1 hour. Then, 1 μl of anti-HA antibody was treated and the reaction proceeded at 4°C overnight. The next day, protein G sepharose beads were added thereto and the reaction proceeded at 4°C for 1 hour. Then, the samples were collected by centrifugation at 6,000 rpm for 1 minute at 4°C. Each of the samples was washed twice with PBS containing 0.1% Triton X-100. The samples were treated with sample buffer and then subjected to Western blotting. Here, Western blotting was performed in the same manner as that performed for the donor cell lysate.

[0155] As a result, an increase in the amount of total tau protein (Tau5) and acetylated tau protein (Tau-acK280) was observed in the culture medium of donor cells treated with acetylated tau protein (Figure 51).

[0156] In addition, other neural cells (recipient cells) were treated with donor cell medium, and lysates of the recipient cells were collected after 1 hour or 20 hours. Western blots were performed on each sample using tau antibodies. Here, Western blotting was performed in the same manner as in Experimental Example 1, and anti-Tau5 antibody (Invitrogen, AHB0042), anti-acetyl-K280 antibody (Anaspec, AS-56077), anti-β-actin antibody (Sigma, A5441), anti-HA antibody (Sigma, #11867423001), and HRP-labeled anti-mouse IgG antibody (Bioxcell, BE0083) were used.

[0157] As a result, tau protein aggregates were observed in lysates of recipient cells treated with culture medium of donor cells treated with acetylated tau protein (Tau-ac-HA) (Figures 52 and 53).

[0158] Experimental Example 16. Identification of the tau seeding inhibitory effect caused by ADEL-Y01h antibody: In vitro To identify the tau seeding inhibitory effect caused by ADEL-Y01h01_v01 antibody in vitro, K280-ac protein fragment (mAC), its aggregate (aAC), or sarkosyl-insoluble fraction from brain tissue of patients with Alzheimer's disease were administered to tau-FRET stable cell lines and the level of tau seeding was measured. IgG and ADEL-Y01h01_v01 antibody were administered to tau-seeded cells, respectively, and comparative analysis was performed.

[0159] First, the aggregate of K280-ac protein fragment to be used for treating cells was prepared as follows: K280-ac protein fragment with a concentration of 25 μM was dissolved in 25 mM DTT solution at 24° C. for 1 hour, and the resulting product was dissolved in a solution of (2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mM, pH 7.4), NaCl (100 mM) and heparin (25 mM) under stirring at 700 rpm and 37° C. using Eppendorf Thermomixer C. Thus, the aggregate of K280-ac protein fragment was prepared.

[0160] Then, HEK293 Tau RD P301S-FRET Biosensor (ATCC CRL-3275) was added at 3.5 × 10 4 Cells / well were dispensed. After 18 hours, it was identified whether about 60% of each well was coated with HEK 293 Tau RD P301S-FRET Biosensor. Then, 8.75 μl of OPTI-MEM, 1.25 μl of Lipofectamine 2000 (Invitrogen), and K280-ac protein fragment, its aggregate, or Sarkosyl insoluble fraction were mixed, and the mixture was reacted at room temperature for 20 minutes. Then, each well was treated with the mixture, and then incubated at a temperature of 37°C for 24 hours. Then, fluorescence wavelength analysis was performed using a CLARIOstar (registered trademark) (BMG Labtech) device.

[0161] As a result, when ADEL-Y01h01_v01 antibody was administered, cells treated with K280-ac protein fragments showed a decrease in integrated FRET density; when ADEL-Y01h01_v01 antibody was administered, cells treated with aggregates of K280-ac protein fragments also showed a decrease in integrated FRET density (Figure 54). In addition, when ADEL-Y01h antibody was administered, cells treated with sarkosyl-insoluble fractions in brain tissues of patients with Alzheimer's disease showed a decrease in integrated FRET density (Figure 55). From these results, it was identified that tau seeding was inhibited when ADEL-Y01h01_v01 antibody was administered.

[0162] Experimental Example 17. Identification of the tau seeding inhibitory effect caused by ADEL-Y01m antibody: In vivo In order to identify the tau seeding inhibitory effect caused by ADEL-Y01m antibody in vivo, 2 weeks after the start of intravenous injection of IgG or ADEL-Y01m antibody, the sarkosyl insoluble fraction from a patient with Alzheimer's disease was administered to the CA1 layer in the left hippocampus of the Tau-P301L dementia mice prepared in Preparation Example 3. The sarkosyl insoluble fraction was administered to the CA1 layer in the left hippocampus of the Tau-P301L dementia mice. Then, each mouse was euthanized to extract brain tissue, which was then frozen and sliced. The brain sections were subjected to immunohistochemical staining with anti-AT8 antibody to check the level of tau seeding.

[0163] Specifically, the sarkosyl-insoluble fragments (3 μl, 3.3 μg / μl) of the brain tissue of a patient with Alzheimer's disease in Braak stage IV were subjected to ultrasonic treatment and injected into the CA1 layer (anterior-posterior: -1.9 mm, medial-lateral: 1.5 mm, left: -1.8 mm) of the left hippocampus of 6-month-old Tau-P301L dementia mice. The Tau-P301L dementia mice were intravenously injected with IgG or ADEL-Y01m antibody at a dose of 20 mg / kg / week, and 2 weeks later, the sarkosyl-insoluble fragments were administered; and the mice were intravenously administered with IgG or ADEL-Y01m antibody once a week from the week of administration of the sarkosyl-insoluble fragments to the 12th week. Here, the sarkosyl-insoluble fragment was injected at a rate of 0.2 μl / min using a 10 μl glass syringe (Hamilton, 0.49 mm, Reno, NV), and the needle was removed after waiting 5 min to prevent reflux. After 12 weeks, each mouse was euthanized and brain tissue was extracted and cut into 30 μm-thick cryosections using a Leica CM1860.

[0164] For immunohistochemical staining, each brain section was washed with buffer A (1% NGS, 0.2% Triton X-100 and 30% H2O2, and PBS). The brain sections were subjected to treatment with PBS containing 1% NGS and 0.2% Triton X-100, and IgG or ADEL-Y01m antibody, and reacted at 4°C overnight. The brain sections were washed several times with PBS solution, and then reacted with secondary antibody (Vector Laboratories) for 1 hour at room temperature. After that, the brain sections were subjected to immunostaining using Vectastain ABC kit (Vector Laboratories), and immunostaining was performed according to the manufacturer's manual. The stained brain sections were analyzed using ImageJ software (NIH, Bethesda, MD), and the three brain sections containing the hippocampus were quantified. The nerve cells stained with anti-AT8 antibody were measured by three blinded examiners on the brain sections used in the experiment, and quantitative analysis was performed at a specific threshold. Three brain sections between breccia-1.75 and breccia-2.25 in seven Tau-P301L dementia mice administered with IgG and eight Tau-P301L dementia mice administered with ADEL-Y01m antibody were used for analysis. For statistical analysis, t-test was used.

[0165] As a result, for Tau-P301L dementia mice administered IgG, strong staining of neuronal cell bodies was observed in the brain regions (cortex, hippocampus) opposite to the side where the patient's insoluble fragment was administered, whereas for Tau-P301L dementia mice administered ADEL-Y01m antibody, reduced staining was observed in the hippocampus and cortex (Figures 56-59).

[0166] Experimental Example 18. Identification of the inhibitory effect of ADEL-Y01m / ADEL-Y01h antibodies on tau aggregation and seeding To identify the tau aggregation inhibitory effect caused by ADEL-Y01m antibody, an in vitro tau aggregation assay was performed. The in vitro generated K18 protein fragment was acetylated by reacting with 1.5 μg P300 and 1 mM acetyl-CoA at a temperature of 30° C. for 3 hours. The monomeric K18 protein fragment was then reacted with 25 μM acetylated K18 protein fragment (K18-P301L) at room temperature for 1 hour. The resultant was then treated with 25 mM heparin 57, HEPES (10 mM, pH 7.4) and NaCl (100 mM) and stirred at 700 rpm to induce the aggregation of tau protein. The ADEL-Y01m antibody was then used to analyze the aggregation of tau and its seeding inhibitory effect through Western blotting and thioflavin-T assay. Thioflavin-T assay identified that treatment with ADEL-Y01h antibody inhibited aggregation of acetylated tau protein compared to aggregation of acetylated tau protein.

[0167] First, for fibrillation reaction, 10-20M acetylated tau protein (2N4R) was incubated at 37°C in a solution obtained by adding heparin (Sigma-Aldrich) and DTT at a concentration of 2mM in 100mM sodium acetate buffer (pH 7.0). Protein and ThT solution (in a 1:1 ratio) were added to each well. ThT fluorescence analysis at various time points was measured using a CLARIOstar® (BMG Labtech, Ortenberg, Germany) at 450nm (excitation) and 510nm (emission) wavelengths.

[0168] Cultured mouse neuronal cells were treated with aggregates of acetylated proteins and Western blotting was performed to identify the results. For the experiments, primary cortical neurons (DIV10) were treated with monomeric K18-P301L, aggregated K18-P301L, or acetylated K18-P301L at a concentration of 3 μg / ml for 24 h. Neurons were pretreated with 3 μg / ml ADEL-Y01m antibody for 30 min prior to K18 protein treatment.

[0169] As a result, it was observed that many tau aggregates invade neuronal cells and induce the aggregation of endogenous tau protein; however, it was identified that such a phenomenon was reduced when treated simultaneously with ADEL-Y01m antibody (Figures 60 and 61).

[0170] Experimental Example 19. Identification of neuroprotective effect caused by ADEL-Y01m antibody To identify the neuroprotective effect caused by ADEL-Y01m antibody, cerebral cortical neurons were first isolated from mouse brain during the embryonic stage. Specifically, 16-day-old mice were euthanized to extract brain tissue, from which cerebral cortex was isolated. Then, cerebral cortical tissue was dissociated in calcium- and magnesium-free Hank's balanced salt solution (HBSS) and incubated in 0.125% trypsin solution at 37°C for 15 minutes. Trypsin was inactivated by treatment with Dulbecco's modified Eagle medium (DMEM) containing 20% ​​fetal bovine serum, and cerebral cortical tissue was finely ground using a pipette. The obtained cell suspension was diluted in NB medium (Neurobasal® medium) supplemented with B27® supplement (GibcoBRL) and dispensed onto plates coated with 50 μg / ml poly-D-lysine (Sigma) and 1 μg / ml laminin (GibcoBRL). The neurons were cultured for 10 days under conditions of 37°C and 5% CO2. Then, the cultured neurons were treated with 3 μg / ml of acetylated K18 protein fragment aggregates and IgG or ADEL-Y01m antibody, and reacted for 24 hours.

[0171] After 24 hours, the supernatant was collected and analyzed using a cytotoxicity detection kit (LDH, Roche Applied Sciences). As a colorimetric assay to quantify cell death, a method was used to measure the activity of lactate dehydrogenase (LDH) released from the cytosol of damaged nerve cells into the supernatant. The absorbance was measured at a wavelength of 490 nm using a Tecan Infinite® 200 instrument. The results were expressed as a percentage of cell viability compared to a negative control (blank).

[0172] In addition, cell viability was measured using the MTT (thiazolyl blue tetrazolium bromide, Sigma-Aldrich, St. Louis, MO, USA) reduction assay. The absorbance at a wavelength of 540 nm was measured using a TecanInfinite® 200 instrument, and the results were expressed as a percentage compared to the negative control (blank).

[0173] In addition, results were obtained from two independent cultures and six wells, and all values ​​were expressed as the mean ± SE of the mean. For statistical analysis, one-way ANOVA with Tukey's multiple comparison test was used.

[0174] As a result, as shown in FIG. 62, high LDH activity was observed in IgG-treated neurons. Meanwhile, decreased LDH activity was observed in ADEL-Y01m antibody-treated neurons compared to IgG-treated neurons. In addition, as shown in FIG. 63, a greatly decreased survival rate was observed in IgG-treated neurons. Meanwhile, a significantly increased survival rate was observed in ADEL-Y01m antibody-treated neurons compared to IgG-treated neurons. From these results, it was identified that ADEL-Y01m antibody exerts a protective effect against damage in neurons caused by the aggregation of acetylated tau protein.

[0175] Experimental Example 20. Identification of the microglial phagocytosis promoting effect caused by ADEL-Y01m antibody To identify the microglial phagocytosis promoting effect caused by ADEL-Y01m antibody, primary microglia were first isolated from the cerebral cortex of 2- to 3-day-old mice and cultured according to the method described in McDonald DR et al., J Neurosci. 1997; 17: 2284-94.

[0176] For analysis of microglial phagocytosis, the acetylated K18 protein fragments were then labeled with HiLyte™ Fluor 488 according to the manufacturer's instructions. For aggregation of HiLyte™ Fluor 488-labeled acetylated K18 protein, the protein was incubated at 37° C. in 100 mM sodium acetate buffer (pH 7.0) containing heparin (Sigma-Aldrich, St. Louis, MO, USA) and 2 mM DTT to induce its aggregation.

[0177] 5 x 10 in a 12-well plate 4 Microglia were dispensed at 1 cell / well and then reacted with acetylated K18 protein fragment aggregates (3 μg / ml) for 2 hours at 37° C. Pretreatment with IgG or ADEL-Y01m antibody at a concentration of 4.5 μg / ml was performed 30 minutes prior to treatment with acetylated K18 protein fragment aggregates. For phagocytosis analysis, cells were detached by treatment with trypsin and then fixed with 1% paraformaldehyde (PFA). For flow cytometry, cells were treated with 200 μl of HBSS solution containing 2% fetal bovine serum and analyzed using a FACSCanto™ II (BD Biosciences) instrument and a 488 fluorescence filter. As a result, enhanced phagocytosis was observed in microglia treated with ADEL-Y01m antibody compared to IgG-treated microglia (FIG. 64).

[0178] statistical analysis Statistical analysis was performed using GraphPad software (GraphPad Prism v7.0 and GraphPad Prism v8.0, GraphPad Softwere, San Diego, CA, USA). Data were analyzed by one-way ANOVA (Tukey's post-hoc test) and Student's t-test. P values ​​lower than 0.05 were considered significant.

[0179] [Accession number] Name of entrusted institution: Korean Collection for Type Cultures (KCTC) Accession number: KCTC14155BP Accession date: March 18, 2020

Claims

1. An anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:7 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:12; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15; an anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 15; An anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13; and An anti-tau antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:

15. An anti-tau antibody or antigen-binding fragment thereof selected from the group consisting of:

2. The anti-tau antibody or antigen-binding fragment thereof according to claim 1, wherein the fragment is any one selected from the group consisting of Fab, scFv, F(ab')2 and Fv.

3. A polynucleotide encoding the anti-tau antibody or antigen-binding fragment thereof of claim 1.

4. An expression vector comprising the polynucleotide of claim 3.

5. A host cell comprising the expression vector of claim 4.

6. 10. A method for producing the anti-tau antibody or antigen-binding fragment thereof described in claim 1, comprising culturing the host cell described in claim 5.

7. A polynucleotide encoding the heavy and light chains of an antibody comprising the heavy and light chain variable regions of claim 1.

8. A hybridoma having accession number KCTC 14155BP.

9. A pharmaceutical composition for preventing or treating a degenerative neurological disease, comprising an anti-tau antibody or an antigen-binding fragment thereof described in claim 1 as an active ingredient.

10. The degenerative neurological disease is a tau protein-mediated neurological disease, wherein the tau protein-mediated neurological disease is tauopathy, primary age-related tauopathy, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Ritiko-Bodig disease, parkinsonism, subacute sclerosing meningitis, lead encephalopathy, tuberous sclerosis, ganglioglioma, ganglioneuroma, meningioangiomatosis, subacute sclerosing panencephalitis, Hallervorden-Spatz disease, or lipofuscinosis, wherein the tauopathy is Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease (PiD), frontotemporal dementia and parkinsonism linked to chromosome 17, 10. The pharmaceutical composition of claim 9, wherein the therapeutic agent is selected from the group of related disorders collectively referred to as FTDP-17 (Fatal Dementia Protein-17), amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), Puger dementia (DP), Gerstmann-Sträussler-Scheinker disease (GSSD), Lewy body disease, chronic traumatic encephalopathy (CTE), or Huntington's disease.

11. 10. The pharmaceutical composition of claim 9, which is administered via any one of the routes of administration selected from the group consisting of intracerebral, intraventricular, intraperitoneal, transdermal, intramuscular, intradural, intravenous, subcutaneous, and nasal routes of administration.

12. The pharmaceutical composition of claim 9, wherein the prevention or treatment comprises administering an anti-tau antibody or antigen-binding fragment thereof described in claim 1 to a subject predicted to develop or currently having a degenerative neurological disease.

13. A composition for diagnosing degenerative neurology, comprising the anti-tau antibody or antigen-binding fragment thereof described in claim 1.

14. A kit for preventing, treating or diagnosing a degenerative neurological disease, comprising an antibody or antigen-binding fragment thereof described in claim 1, a polynucleotide described in claim 3, an expression vector described in claim 4, or a host cell described in claim 5.

15. 2. Use of the antibody or antigen-binding fragment thereof described in claim 1 for the preparation of a medicament used for preventing or treating a degenerative neurological disease.

Citation Information

Patent Citations

  • antibodies against tau

    JP2015530971A

  • Modified tau protein fragment and use thereof

    KR1020180072579A

  • Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies

    US20130251731A1